Table 3.

Risk factors affecting nab-paclitaxel monotherapy related adverse events and efficacy outcomes by meta-regression analysis

Effect Index	Risk Factors	Coef. value	Std. Err.	T value	P value	95% Confidence Interval
Incidence of neutropenia 3/4 grade	Her-2 negative	−0.136	0.063	−2.14	0.046	−0.268 to −0.003
Incidence of leukopenia all grades	Treatment line	0.366	0.148	2.48	0.056	−0.014 to 0.746
Incidence of neuropathy 3/4 grade	Nab-paclitaxel dosage	0.201	0.107	1.87	0.078	−0.025 to 0.427
Incidence of fatigue all grades	Treatment line	−0.239	0.100	−2.40	0.032	−0.455 to − 0.024
ORR	Treatment line	−0.180	0.059	−3.03	0.006	−0.302 to − 0.058
	Nab-paclitaxel dosage	0.171	0.081	2.11	0.044	0.005 to 0.338
CBR	Treatment line	−0.176	0.077	−2.29	0.037	−0.340 to − 0.012
PFS	Treatment line	1.398	0.635	2.20	0.045	0.036 to 2.760
	Nab-paclitaxel dosage	2.683	1.114	2.41	0.030	0.295 to 5.071
OS	Treatment line	−18.909	8.210	−2.30	0.040	−36.797 to −1.021